Primovist, eovist: What to expect?

Journal of Hepatology

Volumn 57, Issue 2, 2012, Pages 421-429

  Van Beers, Bernard E ^a   Pastor, Catherine M ^b   Hussain, Hero K ^c  

^a Service de Médecine Interne Pôle Infectieux Hôpitaux Universitaires Paris Nord Val de Seine   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Contrast media; Gadolinium ethoxybenzyl DTPA; Liver cirrhosis; Liver function tests; Liver neoplasms; Magnetic resonance imaging

Indexed keywords

ECHOVIST; FERUCARBOTRAN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOXETIC ACID; INDOCYANINE GREEN; MEBROFENIN TC 99M; MULTIDRUG RESISTANCE PROTEIN 2; SUPERPARAMAGNETIC IRON OXIDE;

BILE DUCT; CELL FUNCTION; DISEASE CLASSIFICATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG UPTAKE; EXTRAVASCULAR SPACE; HEADACHE; HUMAN; INJECTION SITE PAIN; LIVER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER METASTASIS; LIVER NODULE; LIVER PERFUSION; LIVER SCINTISCANNING; LIVER SINUSOID; LIVER TUMOR; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TASTE AVERSION; VASODILATATION;

BILE DUCT DISEASES; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING;

EID: 84863987369     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.01.031     Document Type: Review

References (85)

1. B.E. Van Beers, B. Gallez, and J. Pringot Contrast-enhanced MR imaging of the liver Radiology 203 1997 297 306
2. B.E. Van Beers, and V. Vilgrain Biomarkers in abdominal imaging Abdom Imaging 34 2009 663 667
3. P. Reimer, G. Schneider, and W. Schima Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications Eur Radiol 14 2004 559 578
4. K.I. Ringe, D.B. Husarik, C.B. Sirlin, and E.M. Merkle Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver Am J Roentgenol 195 2010 13 28
5. S. Gschwend, W. Ebert, M. Schultze-Mosgau, and J. Breuer Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment Invest Radiol 46 2011 556 566
6. G. Schuhmann-Giampieri, H. Schmitt-Willich, W.R. Press, C. Negishi, H.J. Weinmann, and U. Speck Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system Radiology 183 1992 59 64
7. M. Rohrer, H. Bauer, J. Mintorovitch, M. Requardt, and H.J. Weinmann Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths Invest Radiol 40 2005 715 724
8. T. Tamada, K. Ito, T. Sone, A. Yamamoto, K. Yoshida, and K. Kakuba Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA J Magn Reson Imaging 29 2009 636 640
9. C.J. Zech, B. Vos, A. Nordell, M. Urich, L. Blomqvist, and J. Breuer Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA Invest Radiol 44 2009 305 310
10. H. Haradome, L. Grazioli, M. Tsunoo, R. Tinti, B. Frittoli, and S. Gambarini Can MR fluoroscopic triggering technique and slow rate injection provide appropriate arterial phase images with reducing artifacts on gadoxetic acid-DTPA (Gd-EOB-DTPA)-enhanced hepatic MR imaging? J Magn Reson Imaging 32 2010 334 340
11. U. Motosugi, T. Ichikawa, H. Sou, K. Sano, S. Ichikawa, and L. Tominaga Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) J Magn Reson Imaging 30 2009 849 854
12. U. Motosugi, T. Ichikawa, K. Sano, H. Sou, K. Onohara, and A. Muhi Double-dose gadoxetic acid-enhanced magnetic resonance imaging in patients with chronic liver disease Invest Radiol 46 2011 141 145
13. R. Hammerstingl, A. Huppertz, J. Breuer, T. Balzer, A. Blakeborough, and R. Carter Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions Eur Radiol 18 2008 457 467
14. M. Port, J.M. Idee, C. Medina, C. Robic, M. Sabatou, and C. Corot Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review Biometals 21 2008 469 490
15. T. Leiner, and W. Kucharczyk NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe J Magn Reson Imaging 30 2009 1357 1363
16. H.J. Weinmann, H. Bauer, T. Frenzel, A. Muhler, and W. Ebert Mechanism of hepatic uptake of gadoxetate disodium Acad Radiol 3 Suppl. 2 1996 S232 S234
17. K.M. Giacomini, S.M. Huang, D.J. Tweedie, L.Z. Benet, K.L. Brouwer, and X. Chu Membrane transporters in drug development Nat Rev Drug Discov 9 2010 215 236
18. M. Leonhardt, M. Keiser, S. Oswald, J. Kuhn, J. Jia, and M. Grube Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters Drug Metab Dispos 38 2010 1024 1028
19. J.E. van Montfoort, B. Stieger, D.K. Meijer, H.J. Weinmann, P.J. Meier, and K.E. Fattinger Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1 J Pharmacol Exp Ther 290 1999 153 157
20. B. Hagenbuch, I.D. Adler, and T.E. Schmid Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X Biochem J 345 2000 115 120
21. M. Roth, A. Obaidat, and B. Hagenbuch OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies Br J Pharmacol 165 2012 1260 1287
22. Z.S. Chen, and A.K. Tiwari Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases FEBS J 278 2011 3226 3245
23. M. Schmitt, R. Kubitz, M. Wettstein, S. Vom Dahl, and D. Haussinger Retrieval of the mrp2 gene encoded conjugate export pump from the canalicular membrane contributes to cholestasis induced by tert-butyl hydroperoxide and chloro-dinitrobenzene Biol Chem 381 2000 487 495
24. U. Beuers, M. Bilzer, A. Chittattu, G.A. Kullak-Ublick, D. Keppler, and G. Paumgartner Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver Hepatology 33 2001 1206 1216
25. G.A. Kullak-Ublick, B. Stieger, and P.J. Meier Enterohepatic bile salt transporters in normal physiology and liver disease Gastroenterology 126 2004 322 342
26. N. Kato, T. Yokawa, A. Tamura, A. Heshiki, W. Ebert, and H.J. Weinmann Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats Invest Radiol 37 2002 680 684
27. A. Huppertz, J. Breuer, L.M. Fels, M. Schultze-Mosgau, G. Sutter, and S. Klein Evaluation of possible drug-drug interaction between gadoxetic acid and erythromycin as an inhibitor of organic anion transporting peptides (OATP) J Magn Reson Imaging 33 2011 409 1622
28. P. Reimer, E.J. Rummeny, K. Shamsi, T. Balzer, H.E. Daldrup, and B. Tombach Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence Radiology 199 1996 177 183
29. T.J. Vogl, S. Kummel, R. Hammerstingl, M. Schellenbeck, G. Schumacher, and T. Balzer Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA Radiology 200 1996 59 67
30. T. Ichikawa, K. Saito, N. Yoshioka, A. Tanimoto, T. Gokan, and Y. Takehara Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease Invest Radiol 45 2010 133 141
31. S.S. Ahn, M.J. Kim, J.S. Lim, H.S. Hong, Y.E. Chung, and J.Y. Choi Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma Radiology 255 2010 459 466
32. M. Di Martino, D. Marin, A. Guerrisi, M. Baski, F. Galati, and M. Rossi Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis Radiology 256 2010 806 816
33. M.J. Kim Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma Gut Liver 5 2010 15 21
34. D. Lowenthal, M. Zeile, W.Y. Lim, C. Wybranski, F. Fischbach, and G. Wieners Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and GD-EOB-DTPA-enhanced MR imaging Eur Radiol 21 2011 832 840
35. Y.K. Kim, H.S. Kwak, C.S. Kim, and Y.M. Han Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid J Magn Reson Imaging 30 2009 437 443
36. J.S. Choi, M.J. Kim, J.Y. Choi, M.S. Park, J.S. Lim, and K.W. Kim Imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium Eur Radiol 20 2010 1052 1060
37. C.J. Zech, L. Grazioli, E. Jonas, M. Ekman, R. Niebecker, and S. Gschwend Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: GD-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden Eur Radiol 19 2009 S753 S763
38. D.B. Husarik, R.T. Gupta, K.I. Ringe, D.T. Boll, and E.M. Merkle Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents Acad Radiol 18 2011 1549 1554
39. Gupta RT, Marin D, Boll DT, Husarik DB, Davis DE, Feuerlein S, et al. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium. Eur J Radiol, 2011 [Epub ahead of print].
40. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
41. A. Forner, R. Vilana, C. Ayuso, L. Bianchi, M. Sole, and J.R. Ayuso Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma Hepatology 47 2008 97 104
42. International Consensus Group for Hepatocellular Neoplasia Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia Hepatology 49 2009 658 664
43. M. Kudo Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology 78 Suppl. 1 2010 87 93
44. S. Kogita, Y. Imai, M. Okada, T. Kim, H. Onishi, and M. Takamura GD-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow Eur Radiol 20 2010 2405 2413
45. U. Motosugi, T. Ichikawa, H. Sou, K. Sano, L. Tominaga, and A. Muhi Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging Radiology 256 2010 151 158
46. K. Sano, T. Ichikawa, U. Motosugi, H. Sou, A.M. Muhi, and M. Matsuda Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging Radiology 261 2011 834 844
47. J.M. Lee, C.J. Zech, L. Bolondi, E. Jonas, M.J. Kim, and O. Matsui Consensus report of the 4th international forum for gadolinium-ethoxybenzyl- diethylenetriamine pentaacetic acid magnetic resonance imaging Korean J Radiol 12 2011 403 415
48. T. Tsuboyama, H. Onishi, T. Kim, H. Akita, M. Hori, and M. Tatsumi Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation Radiology 255 2010 824 833
49. S.A. Lee, C.H. Lee, W.Y. Jung, J. Lee, J.W. Choi, and K.A. Kim Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of GD-EOB-DTPA-enhanced MRI: initial experience Magn Reson Imaging 29 2011 83 90
50. G. Zollner, M. Wagner, P. Fickert, D. Silbert, A. Fuchsbichler, and K. Zatloukal Hepatobiliary transporter expression in human hepatocellular carcinoma Liver Int 25 2005 367 379
51. A. Kitao, Y. Zen, O. Matsui, T. Gabata, S. Kobayashi, and W. Koda Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging - correlation with molecular transporters and histopathologic features Radiology 256 2010 817 826
52. F. Vasuri, R. Golfieri, M. Fiorentino, E. Capizzi, M. Renzulli, and A.D. Pinna OATP 1B1/1B3 expression in hepatocellular carcinomas treated with orthotopic liver transplantation Virchows Arch 459 2011 141 146
53. A. Kitao, O. Matsui, N. Yoneda, K. Kozaka, R. Shinmura, and W. Koda The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging Eur Radiol 21 2011 2056 2066
54. J.Y. Choi, M.J. Kim, Y.N. Park, J.M. Lee, S.K. Yoo, and S.Y. Rha Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics AJR Am J Roentgenol 197 2011 399 405
55. J. Zucman-Rossi Molecular classification of hepatocellular carcinoma Dig Liver Dis 42 Suppl. 3 2010 S235 S241
56. Y. Shibayama, K. Nakano, H. Maeda, M. Taguchi, R. Ikeda, and M. Sugawara Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib Biol Pharm Bull 34 2011 433 435
57. S. Vander Borght, L. Libbrecht, H. Blokzijl, K.N. Faber, H. Moshage, and R. Aerts Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver J Pathol 207 2005 471 482
58. C.J. Zech, L. Grazioli, J. Breuer, M.F. Reiser, and S.O. Schoenberg Diagnostic performance and description of morphological features of focal nodular hyperplasia in GD-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial Invest Radiol 43 2008 504 511
59. N. Doi, Y. Tomiyama, T. Kawase, S. Nishina, N. Yoshioka, and Y. Hara Focal nodular hyperplasia-like nodule with reduced expression of organic anion transporter 1B3 in alcoholic liver cirrhosis Intern Med 50 2011 1193 1199
60. J. Fidler, and D. Hough Hepatocyte-specific magnetic resonance imaging contrast agents Hepatology 53 2011 678 682
61. A. Sakamoto, H. Hayashi, I. Sakamoto, I. Isomoto, S. Eguchi, and M. Takatsuki Multiple hepatocellular adenomas in a patient with glycogen storage disease type I: various enhancement patterns in MRI with Gd-EOB-DTPA Abdom Imaging 37 2012 239 243
62. A. Huppertz, S. Haraida, A. Kraus, C.J. Zech, J. Scheidler, and J. Breuer Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations Radiology 234 2005 468 478
63. M. Ronot, S. Bahrami, J. Calderaro, D.C. Valla, P. Bedossa, and J. Belghti Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification Hepatology 53 2011 1182 1191
64. K.I. Ringe, D.B. Husarik, R.T. Gupta, D.T. Boll, and E.M. Merkle Hepatobiliary transit times of gadoxetate disodium (Primovist) for protocol optimization of comprehensive MR imaging of the biliary system - what is normal? Eur J Radiol 79 2011 201 205
65. N.K. Lee, S. Kim, J.W. Lee, S.H. Lee, D.H. Kang, and G.H. Kim Biliary MR imaging with Gd-EOB-DTPA and its clinical applications Radiographics 29 2009 1707 1724
66. A.D. Smith, and J.C. Veniero Gd-EOB-DTPA as a functional MR cholangiography contrast agent: imaging gallbladder filling in patients with and without hepatobiliary dysfunction J Comput Assist Tomogr 35 2011 439 445
67. Tamada T, Ito K, Sone T, Kanki A, Sato T, Higashi H. GD-EOB-DTPA-enhanced MR imaging: evaluation of biliary and renal excretion in normal and cirrhotic livers. Eur J Radiol, 2010 [Epub ahead of print].
68. F.T. Tschirch, A. Struwe, H. Petrowsky, I. Kakales, B. Marincek, and D. Weishaupt Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma Eur Radiol 18 2008 1577 1586
69. K.I. Ringe, R.T. Gupta, C.M. Brady, C.M. Massey, A. Hahn, and M. Galanski Respiratory-triggered three-dimensional T2-weighted MR cholangiography after injection of gadoxetate disodium: is it still reliable? Radiology 255 2010 451 458
70. A. Zipprich, O. Kuss, S. Rogowski, G. Kleber, E. Lotterer, and T. Seufferlein Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis Gut 59 2010 963 968
71. J. Belghiti, and S. Ogata Assessment of hepatic reserve for the indication of hepatic resection J Hepatobiliary Pancreat Surg 12 2005 1 3
72. R.J. Bennink, W. de Graaf, and T.M. van Gulik Toward a total and regional scintigraphic liver function test enabling assessment of future remnant liver function Nucl Med Commun 32 2011 669 671
73. N.H. Hendrikse, F. Kuipers, C. Meijer, R. Havinga, C.M. Bijleveld, and W.T. van der Graaf In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein Cancer Chemother Pharmacol 54 2004 131 138
74. W. de Graaf, S. Hausler, M. Heger, T.M. van Ginhoven, G. van Cappellen, and R.J. Bennink Transporters involved in the hepatic uptake of (99m)Tc-mebrofenin and indocyanine green J Hepatol 54 2011 738 745
75. H.K. Ryeom, S.H. Kim, J.Y. Kim, H.J. Kim, J.M. Lee, and Y.M. Chang Quantitative evaluation of liver function with MRI using Gd-EOB-DTPA Korean J Radiol 5 2004 231 239
76. U. Motosugi, T. Ichikawa, H. Sou, K. Sano, L. Tominaga, and T. Kitamura Liver parenchymal enhancement of hepatocyte-phase images in GD-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30 2009 1042 1046
77. H. Nilsson, A. Nordell, R. Vargas, L. Douglas, E. Jonas, and L. Blomqvist Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI J Magn Reson Imaging 29 2009 1323 1331
78. N. Tsuda, M. Okada, and T. Murakami New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on GD-EOB-DTPA-enhanced MRI Eur J Radiol 73 2010 137 142
79. N. Tsuda, and O. Matsui Cirrhotic rat liver: reference to transporter activity and morphologic changes in bile canaliculi - gadoxetic acid-enhanced MR imaging Radiology 256 2010 767 773
80. R. Materne, A.M. Smith, F. Peeters, J.P. Dehoux, A. Keyeux, and Y. Horsmans Assessment of hepatic perfusion parameters with dynamic MRI Magn Reson Med 47 2002 135 142
81. B.E. Van Beers, R. Materne, L. Annet, L. Hermoye, C. Sempoux, and F. Peeters Capillarization of the sinusoids in liver fibrosis: noninvasive assessment with contrast-enhanced MRI in the rabbit Magn Reson Med 49 2003 692 699
82. L. Liu, and K.S. Pang An integrated approach to model hepatic drug clearance Eur J Pharm Sci 29 2006 215 230
83. B.E. Van Beers, C. Grandin, S. Pauwels, I. Mottet, J.F. Goudemant, and M. Delos Gd-EOB-DTPA enhancement pattern of hepatocellular carcinomas in rats: comparison with Tc-99m-IDA uptake J Magn Reson Imaging 4 1994 351 354
84. P. Millet, M. Moulin, B. Stieger, Y. Daali, and C.M. Pastor How organic anions accumulate in hepatocytes lacking Mrp2: evidence in rat liver J Pharmacol Exp Ther 336 2011 624 632
85. B. Stieger, M. Heger, W. de Graaf, G. Paumgartner, and T. van Gulik The emerging role of transport systems in liver function tests Eur J Pharmacol 675 2012 1 5